Supplements
NAD boosters: NAD, NR, NMN and infusions
On this page
The coenzyme, precursors, route and outcome have different meanings
| Term | What it describes | Evidence boundary |
|---|---|---|
| NAD | Nicotinamide adenine dinucleotide, a coenzyme involved in cellular reactions. | Biological importance does not prove benefit from taking more.[1] |
| NR | Nicotinamide riboside, an oral precursor tested in human trials. | A change in NAD metabolism is not a lifespan result.[2] |
| NMN | Nicotinamide mononucleotide, a different oral precursor. | Results depend on the studied population and outcome.[3] |
| NAD infusion | An injectable preparation and route. | Oral precursor studies do not establish injectable safety or benefit.[5] |
| Biomarker versus clinical outcome | A biological measurement versus how someone feels, functions or survives. | Short biochemical studies cannot establish years of clinical outcomes.[4] |
What NAD does, and how this differs from an anti-aging claim
NIH describes niacin, or vitamin B3, as a nutritional source used to form NAD. This coenzyme helps enzymes carry out metabolic reactions, including transferring energy from nutrients into cellular ATP. NAD also participates in other cellular processes. A normal biological role does not prove that an added product prolongs life.[1]
Meeting a nutritional requirement and testing an anti-aging intervention are separate questions. The phrase “cellular energy” does not itself measure a person’s fatigue, function or lifespan.[1]
A specific NMN finding does not apply automatically to everyone
Yoshino and colleagues’ 2021 ten-week trial studied postmenopausal women with prediabetes and overweight or obesity. NMN improved a measured muscle insulin-sensitivity response. That defined metabolic finding differs from claiming that NMN cures diabetes, benefits every adult or lengthens life. The population, measurement and short follow-up constrain interpretation.[3]
Injectable NAD needs its own evidence and preparation safeguards
FDA warns that ingredients unsuitable for sterile compounding, including food-grade NAD+, can create contamination concerns. Reports after injectable NAD+ use included severe chills, shaking, vomiting and fatigue, consistent with concerns about endotoxin exposure. This is a preparation and safety issue, not proof that every formulation has identical risk.[5]
A compound’s role inside the body does not certify an outside preparation as sterile. Findings about swallowing NR or NMN cannot establish the effects of infusing NAD. Route, ingredients, sterility and intended outcomes need their own evidence.[5]
A promising functional signal still needs replication
A 2022 NMN trial in older men raised blood NAD-related measures and reported nominal improvements in gait speed and one grip test, with no body-composition effect. Twenty-two participants had a protocol deviation after six weeks; only twenty completed twelve weeks. Those details constrain interpretation. Biochemical response and exploratory functional findings do not establish longer life or broad reversal of aging.[6]
Evidence & uncertainty
Human lifespan extension is not established by the selected evidence. Short trials report changes in NAD metabolism or particular metabolic measures; these are not interchangeable with lasting clinical benefit. Long-term safety, wider population effects and injectable-product claims remain unresolved. Source access limits are recorded with each reference.[4]
Selected-source overview · Independent review pendingPublished questions
Are NAD, NR and NMN the same compound?
Selected-source overview · Independent review pending. Read the evidence context.
No. NAD is the coenzyme; NR and NMN are different related precursors. Evidence needs the actual compound and preparation.[1][2][3]
Evidence behind this answer
- Niacin — Health Professional Fact Sheet
agency nutrient explanation · Date not stated
Selected relevant official page passages inspected · Introduction: niacin forms, NAD coenzyme and nutrient-energy metabolism - Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults
randomized crossover trial · 2018
Indexed original abstract inspected; full methods and disclosures not independently appraised · Original abstract: short-term oral NR, NAD metabolism, tolerability and preliminary physiology - Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women
randomized trial · 2021
Indexed original abstract inspected; full methods, comments and disclosures not independently appraised · Original abstract: ten-week trial in postmenopausal women with prediabetes and overweight or obesity
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Does raising a NAD-related biomarker prove a person will live longer?
Selected-source overview · Independent review pending. Read the evidence context.
No. The selected NR trial measured short-term NAD metabolism and physiology. It did not establish longer human lifespan.[2]
Evidence behind this answer
- Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults
randomized crossover trial · 2018
Indexed original abstract inspected; full methods and disclosures not independently appraised · Original abstract: short-term oral NR, NAD metabolism, tolerability and preliminary physiology
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Does the 2021 NMN insulin-sensitivity result establish benefit for every adult?
Selected-source overview · Independent review pending. Read the evidence context.
No. The trial concerned postmenopausal women with prediabetes and overweight or obesity, over ten weeks. Wider outcomes need separate evidence.[3]
Evidence behind this answer
- Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women
randomized trial · 2021
Indexed original abstract inspected; full methods, comments and disclosures not independently appraised · Original abstract: ten-week trial in postmenopausal women with prediabetes and overweight or obesity
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Can oral NR or NMN studies validate NAD infusions?
Selected-source overview · Independent review pending. Read the evidence context.
No. An injectable product is a different preparation and route. Oral findings do not establish infusion safety, sterility or benefit.[5]
Evidence behind this answer
- FDA reminds compounders to use ingredients suitable for sterile compounding
agency compounding safety notice · Date not stated
Selected relevant official page passages inspected · Food-grade NAD+, sterility/endotoxin concerns and reported reactions
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Do short trials with favorable tolerability establish lifelong NMN safety?
Selected-source overview · Independent review pending. Read the evidence context.
No. The selected review’s trials lasted days to months. That follow-up cannot establish years of safety or rare long-term effects.[4]
Evidence behind this answer
- Safety and Metabolism-Related Outcomes of Oral Nicotinamide Mononucleotide Supplementation in Adults: A Systematic Review and Meta-Analysis
systematic review of randomized trials · 2026
Indexed original abstract and methods introduction inspected; direct full-text retrieval returned an access check · July 2026 indexed original abstract and methods introduction: follow-up, safety, metabolic uncertainty and protocol amendment
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Does the importance of NAD in metabolism prove an anti-aging supplement works?
Selected-source overview · Independent review pending. Read the evidence context.
No. A coenzyme role is a biological explanation. Supplement benefit requires trials of the actual product and relevant human outcomes.[1]
Evidence behind this answer
- Niacin — Health Professional Fact Sheet
agency nutrient explanation · Date not stated
Selected relevant official page passages inspected · Introduction: niacin forms, NAD coenzyme and nutrient-energy metabolism
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Does food-grade NAD automatically qualify as a sterile injectable ingredient?
Selected-source overview · Independent review pending. Read the evidence context.
No. FDA flags unsuitable food-grade ingredients and contamination concerns in sterile compounding. Food use does not establish injectable suitability.[5]
Evidence behind this answer
- FDA reminds compounders to use ingredients suitable for sterile compounding
agency compounding safety notice · Date not stated
Selected relevant official page passages inspected · Food-grade NAD+, sterility/endotoxin concerns and reported reactions
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Is meeting vitamin B3 needs the same claim as extending lifespan with NAD boosters?
Selected-source overview · Independent review pending. Read the evidence context.
No. Nutritional adequacy and a lifespan intervention are different questions. NIH’s description of niacin metabolism does not establish lifespan extension.[1]
Evidence behind this answer
- Niacin — Health Professional Fact Sheet
agency nutrient explanation · Date not stated
Selected relevant official page passages inspected · Introduction: niacin forms, NAD coenzyme and nutrient-energy metabolism
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
An NR trial demonstrated a biochemical response, with limited clinical scope
Martens and colleagues’ 2018 randomized, placebo-controlled crossover study tested oral NR over short periods in healthy middle-aged and older adults. It reported stimulated NAD metabolism and short-term tolerability. The authors described initial physiological findings as reasons for further trials. This was not a human lifespan-extension trial or proof of universal clinical benefit.[2]
Short-term tolerability is narrower than lifelong safety
A July 2026 systematic review describes trials lasting from 14 days to 24 weeks. Its indexed original abstract reports generally favorable short-term tolerability, with inconsistent or limited broader metabolic findings. These are bounded observations, not confirmation of permanent safety, lifespan extension or every advertised benefit.[4]
The indexed methods note a registered-protocol amendment prioritizing safety. Independent full trial extraction and risk-of-bias appraisal were not completed here. A review can reuse trials reported separately on this page; a review and a trial should not automatically be counted as independent experiments.[4]
A named trial found a functional signal in peripheral artery disease
NICE is this trial’s name, separate from the UK guideline agency. It randomized ninety people with peripheral artery disease, a circulation disorder, to NR, NR plus resveratrol or placebo for six months. NR alone improved six-minute walking distance by 17.6 metres relative to placebo; the combination’s primary comparison did not clearly improve. This is a functional outcome beyond a blood NAD measurement.[7]
It was an early-stage trial using prespecified one-sided testing for benefit at P below 0.10, a more permissive setup than usual confirmatory testing. NR’s P value was 0.08; its one-sided 90% confidence interval had a lower bound of 1.8 metres and no finite upper bound. Larger effects in an adherent subgroup were post hoc, not a second trial. The American Heart Association funded the study, and companies supplied products. Confirmation is needed in this clinical population; ordinary anti-aging benefit and replacement of established artery-disease care were not established.[7]
References
- Niacin — Health Professional Fact Sheet
Agency nutrient explanation
NIH Office of Dietary Supplements · Content/publication date: not stated
Accessed: 2026-10-07 UTC · Selected relevant official page passages inspected
Cited sections: Introduction: niacin forms, NAD coenzyme and nutrient-energy metabolismPhysiology and nutrition, not a lifespan-extension trial.
- Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults
Randomized crossover trial
Martens CR and colleagues · Content/publication date: 2018
Accessed: 2026-10-07 UTC · Indexed original abstract inspected; full methods and disclosures not independently appraised
Cited sections: Original abstract: short-term oral NR, NAD metabolism, tolerability and preliminary physiologySelected short human trial. Biochemical response is not a lifespan outcome.
- Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women
Randomized trial
Yoshino M and colleagues · Content/publication date: 2021
Accessed: 2026-10-07 UTC · Indexed original abstract inspected; full methods, comments and disclosures not independently appraised
Cited sections: Original abstract: ten-week trial in postmenopausal women with prediabetes and overweight or obesitySpecific population and metabolic measurement, not a cure or lifespan trial.
- Safety and Metabolism-Related Outcomes of Oral Nicotinamide Mononucleotide Supplementation in Adults: A Systematic Review and Meta-Analysis
Systematic review of randomized trials
Yang W and colleagues · Content/publication date: 2026
Accessed: 2026-10-07 UTC · Indexed original abstract and methods introduction inspected; direct full-text retrieval returned an access check
Cited sections: July 2026 indexed original abstract and methods introduction: follow-up, safety, metabolic uncertainty and protocol amendmentNo independent full-text extraction, risk-of-bias or certainty grading. Exact overlap with separately listed trials remains to be mapped.
- FDA reminds compounders to use ingredients suitable for sterile compounding
Agency compounding safety notice
US FDA · Content/publication date: not stated
Accessed: 2026-10-07 UTC · Selected relevant official page passages inspected
Cited sections: Food-grade NAD+, sterility/endotoxin concerns and reported reactionsUS preparation-safety notice, not efficacy evidence or a blanket verdict about all NAD products.
- NMN and physiological function in healthy older men
Randomized trial
Igarashi and colleagues · Content/publication date: 2022
Accessed: 2026-10-13 UTC · Selected relevant page text, guideline passages, or publication abstract inspected
Cited sections: 2022 abstract and flow diagram: NAD response; nominal gait/grip changes; protocol deviationIndustry-linked author employment disclosed; 22 protocol deviations after6weeks; not a longevity-outcome trial.
- Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial
Randomized phase ii trial
McDermott MM and colleagues · Content/publication date: 2024
Accessed: 2026-10-20 UTC · Original abstract and actual Methods/Results/statistical plan/funding read. Ninety PAD participants in three arms; one-sided P<0.10 and 90% confidence bounds prespecified. Publisher correction 12 August 2024 restores trial-registration text only; no changed effect estimate. Primary/secondary/posthoc findings kept separate.
Cited sections: Actual primary six-month comparisons; one-sided statistical plan; adherence; funding; publisher correction
Scope & review
- Population
- Selected healthy middle-aged/older NR participants; separate postmenopausal prediabetic NMN population; short adult trials
- Exposure or intervention
- Oral NR and NMN; NAD physiology; injectable NAD preparation risks distinguished
- Comparison
- Placebo in selected oral trials; no independent infusion-benefit comparison
- Outcomes
- NAD metabolism, measured insulin sensitivity and short-term tolerability; lifespan and broad clinical benefit not established
- Timeframe
- Selected short trials and a 2026 review covering 14 days to 24 weeks; not lifelong follow-up
- Jurisdiction
- International research; US NIH nutritional explanation and FDA compounding-safety context
Selected-source educational explanation. Official guidance, original study findings and editorial interpretation are distinguished. No exhaustive search, independent systematic synthesis or qualified medical review has been completed.
Sources checked on their individual access dates. Selected sources were checked; ongoing surveillance and qualified review have separate statuses on the coverage page.
Revision history
- 2026-10-07 UTC: Added a sourced explanation in a bounded ten-article batch; qualified review remains pending.
- 2026-10-13 UTC: Deepened categories, selected primary-source evidence, comparator interpretation and scientific uncertainty; preserved prior IDs and citations.
- 2026-10-20 UTC: Added useful product/category distinctions and bounded original comparative evidence after twenty-guide audit and neighboring/pending checks; previous content retained and qualified review remains pending.
What this article still leaves open
- Independent full-text appraisal, disclosure review and exact overlap between trials and the selected review.
- Larger, longer trials of meaningful clinical and functional outcomes, with defined populations and formulations.
- Injectable-route efficacy and long-term safety; jurisdiction-specific regulatory status needs a separate current check.
Suggest a correction
Submit a content correction to the editorial queue, or download a local note. Leave out personal medical details. Submitted text is stored privately with a browser receipt session and is visible to this browser and the editor. Clearing cookies removes access to your submission history. This is not an account or a medical service.
Your submitted corrections for this article
Explore the topic map
Browse the health domains connected to this article. The map also identifies topics whose articles remain unwritten.